ArticleDiscover oncology2025
Current perspectives and global trends of nanotechnology in advanced breast cancer: a bibliometric and visualized analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite advancements in diagnosis and treatment methods for advanced breast cancer (ABC), a more extensive breast cancer (BC) stage with heterogeneity in clinical features, its clinical management remains a substantial challenge. Furthermore, although research on nanotechnology (NT)-based ABC treatment has recently gained significant attention, studies intuitively examining this discipline are quite scarce. Therefore, we aimed to comprehensively assess the current status and emerging trends in NT-based ABC treatments. Studies focusing on NT application in ABC treatment were retrieved from the Web of Science Core Collection (WOSCC) database. Bibliometric and visual analyses were then performed using CiteSpace and VOSviewer software. Herein, 3531 papers were included. From 2005 to 2024, annual publications on NT use in ABC treatment increased, mostly from China and the United States, accounting for 1139 and 1032 publications, respectively. Furthermore, the Chinese Academy of Sciences (CAS) was the most prominent institution, with Yaping Li as the leading author in studies on NT-based ABC treatment. Additionally, the Journal of Controlled Release had the highest number of publications while Cancer Research was the most cited journal. Moreover, the most widely studied areas were therapeutic intervention and metastatic breast cancer (MBC), while solid lipid nanoparticles (LNPs), targeted therapy, and tumor microenvironment (TME) were the latest research focal points. This study provides a comprehensive overview of NT use in ABC treatment over the past two decades. Specifically, it evaluated the contributions of countries, authors, and institutions, and identified research hotspots and emerging frontiers, providing novel perspectives and laying the groundwork for future investigations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.